Fertility preservation via cortical strip banking & autotransplantation
Ovarian tissue cryopreservation (OTC) is the only fertility-preservation option available for pre-pubertal girls and for patients who need chemotherapy to start immediately, with no time for the 2–3 weeks required for ovarian stimulation and egg or embryo freezing. A laparoscopic surgeon removes one whole ovary or several cortical biopsies before gonadotoxic treatment begins.
Chemotherapy (especially alkylating agents like cyclophosphamide) and pelvic radiotherapy are gonadotoxic — they destroy primordial follicles, the non-renewable pool of oocytes a woman is born with (~1–2 million at birth, declining to ~300,000 by puberty and ~1,000 at menopause). Unlike sperm or bone marrow, oocytes cannot be regenerated.
Standard fertility preservation (egg or embryo freezing) requires 2–3 weeks of hormonal stimulation, is not usable before puberty, and may be contraindicated in hormone-sensitive cancers. Ovarian tissue cryopreservation sidesteps all three limitations: it requires no stimulation, no delay to treatment, and works in children as young as a few months old.
OTC is the ONLY fertility-preservation method available to prepubertal girls, since they have no mature eggs to retrieve and cannot undergo ovarian stimulation.
Under general anesthesia, 2–3 small (5–10mm) incisions are made in the abdomen. A laparoscope (camera) and grasping/cutting instruments are introduced through trocar ports.
Two surgical strategies exist: • Unilateral oophorectomy: the entire ovary is removed, maximizing the number of follicles banked — typical when very high-dose or urgent treatment is planned • Cortical biopsy: strips of cortex are shaved from the surface of one or both ovaries, leaving the medulla and stroma intact for continued natural function during less aggressive treatment
The excised tissue is placed immediately in cold transport medium (4°C) and transported to the processing laboratory within a strict cold-ischemia window — ideally under 2 hours — to minimize follicle loss before cryoprotectant exposure.
OTC is offered when the risk of premature ovarian insufficiency is high: hematopoietic stem cell transplant conditioning, whole-abdominal or pelvic radiotherapy, high cumulative alkylating-agent doses, or when there is no time to delay treatment for stimulation cycles.
Because the procedure carries a small anesthesia and surgical risk and removes ovarian tissue that might otherwise remain untouched, patient selection is guided by validated risk-prediction tools (e.g. the Edinburgh criteria) that weigh cancer type, planned treatment intensity, and baseline ovarian reserve markers (AMH, antral follicle count).
Primordial follicles are not evenly distributed through the ovary — they are concentrated almost exclusively in the outer cortex, a layer only 1–2mm thick. In the laboratory, the retrieved tissue is trimmed and sliced into thin strips engineered to maximize follicle yield while allowing cryoprotectant to permeate the entire strip in minutes, not hours.
The ovary has two histologically distinct zones: the medulla (central, vascular, containing large blood vessels and stroma but essentially no follicles) and the cortex (outer shell, densely packed with primordial and early primary follicles embedded in fibrous stroma).
Because the vasculature runs through the medulla, and cryopreservation cannot yet successfully freeze whole intact organs with their blood supply, only the cortex is banked. The medulla is dissected away and discarded (or in some protocols, examined separately for research).
Using a scalpel or dermatome under sterile technique, the surgical team parses the cortex into flat strips roughly 1cm × 1cm in surface area, cut to a controlled thickness.
Strip thickness is the single most important physical variable in the entire OTC workflow, because it governs cryoprotectant diffusion distance. Cryoprotectant agents (CPAs) must fully permeate the tissue before cooling begins, or unprotected water in the strip core will form damaging ice crystals.
Diffusion time scales with the square of distance, so doubling strip thickness roughly quadruples the time — or the concentration gradient — needed for the CPA front to reach the center:
• <1mm strips: CPA fully penetrates in minutes; but too little tissue is banked per strip, requiring many more strips and more cutting-related follicle loss at the edges • 1–2mm strips: the clinical standard — a practical balance between adequate CPA penetration (~20–30 min equilibration) and follicle yield per strip • >2mm strips: center of the strip may remain under-protected at the time of freezing, risking intracellular ice formation and follicle death precisely in the strip core
A strip twice as thick does not need twice the equilibration time — it needs roughly four times as long, because diffusion distance scales with the square root of time. This is why 1–2mm is treated as a hard clinical ceiling.
Before the bulk of tissue is committed to cryopreservation, a small reference strip is typically sent for histological analysis: follicle density is counted per mm² of cortex, follicle morphology is graded (intact vs degenerating), and in some centers immunohistochemistry confirms follicle viability markers.
Follicle density varies enormously with patient age: a cortical strip from a young girl may contain many thousands of densely packed primordial follicles, while a strip from a woman in her late 30s may contain a fraction of that density — informing counseling about the realistic reproductive potential of the banked tissue.
Water is the enemy of cryopreservation. If cooled naively, water inside and around cells forms sharp ice crystals that shred membranes and organelles. Two engineering solutions exist to avoid this: slow, controlled-rate freezing that dehydrates cells gently before ice forms, or vitrification — cooling so fast that water solidifies into a glass with no crystalline structure at all.
The historically dominant method uses a programmable freezer to cool tissue at a precisely controlled rate — typically around −0.3°C per minute from 0°C down to about −40°C, followed by faster cooling to the plunge temperature.
The strategy relies on a physical principle: as extracellular ice begins to form slowly, it concentrates solutes in the remaining unfrozen liquid, creating an osmotic gradient that draws water out of cells gradually. This "solution effect" dehydrates the follicles before intracellular ice has a chance to nucleate.
Done correctly, slow freezing produces almost no intracellular ice — but the process takes 2–3 hours in a controlled-rate freezer, uses lower cryoprotectant concentrations (less toxic), and remains the most widely validated protocol behind the majority of the >200 live births reported worldwide.
Vitrification takes the opposite strategy: cool so explosively fast (often by plunging tissue directly into liquid nitrogen, sometimes after blotting to a thin film) that water molecules have no time to organize into a crystal lattice at all. Instead, the tissue solidifies into an amorphous, glass-like state.
To prevent ice formation at achievable cooling rates, vitrification requires much higher cryoprotectant concentrations (often a cocktail of DMSO + ethylene glycol + sucrose) — introducing a toxicity/exposure-time tradeoff that must be carefully managed, especially for thicker strips where full CPA penetration takes longer to achieve.
Vitrification takes minutes rather than hours and, when penetration is adequate, produces excellent ultrastructural preservation of the delicate primordial follicle basement membrane — but tissue thickness above ~2mm sharply increases the risk of an under-protected, ice-prone core.
Neither method has been definitively proven superior in large randomized trials; many centers now use vitrification for its speed and simplicity, while slow-freeze remains the protocol with the longest clinical track record.
Intracellular ice crystals are lethal because their growing, jagged crystal faces physically puncture the plasma membrane, mitochondria, and — most critically for a primordial follicle — the thin basement membrane separating the oocyte from its single layer of supporting granulosa cells. Once that architecture is disrupted, the follicle cannot survive reactivation even if it looks intact under a microscope immediately after thaw.
Because ice nucleates preferentially wherever cryoprotectant concentration is lowest, the geometric center of an over-thick strip — the last place CPA reaches — is exactly where ice damage concentrates. This is the direct mechanistic link between strip thickness and follicle survival.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
| Slow-Freeze | Programmable rate freezer, −0.3°C/min | Gradual extracellular ice draws water out of cells before intracellular freezing | Longest clinical track record, lower CPA toxicity |
| Vitrification | Direct plunge into LN₂, >2,000°C/min | Water solidifies as amorphous glass, no crystal lattice forms | Minutes not hours, excellent ultrastructure if CPA fully penetrated |
| Cryoprotectants used | DMSO, ethylene glycol, propanediol | Replace intracellular water, depress freezing point, limit ice nucleation | Combined with sucrose as extracellular osmotic buffer |
| Critical failure mode | Strip thickness >2mm | CPA fails to reach strip core before cooling begins | N/A — drives the 1–2mm thickness standard |
Once vitrified or slow-frozen, cortical strips are sealed into labeled straws, cryovials, or specialized carriers and transferred into liquid nitrogen storage at −196°C. At this temperature all biochemical and metabolic activity effectively stops — the tissue enters a state of suspended animation that can, in principle, last for decades.
At −196°C (the boiling point of liquid nitrogen at atmospheric pressure), molecular motion is so slow that chemical reaction rates — including the reactions that would normally degrade DNA, proteins, and membranes over time — become negligible. In a properly vitrified or slow-frozen state with minimal residual ice, tissue is essentially frozen in time.
Storage tanks (dewars) hold tissue either submerged in liquid-phase nitrogen or suspended in the vapor phase above it (vapor-phase storage avoids any risk of cross-contamination between patient samples and is now the more common standard). Continuous monitoring systems track liquid nitrogen levels and temperature, with backup alarm systems and redundant tanks protecting irreplaceable tissue.
Ovarian tissue cryopreservation was first attempted in animal models in the 1990s, and the first human live birth following OTC and autotransplantation was reported by Jacques Donnez's team in 2004. For the next 15 years, professional societies classified the technique as "experimental," reflecting the relatively small number of cases and the evolving understanding of graft longevity.
By 2019, with well over 130 live births documented and growing evidence of safety and efficacy, the American Society for Reproductive Medicine (ASRM) formally removed the "experimental" designation — a landmark decision that expanded insurance coverage and clinical availability. Since then, the cumulative total of live births attributed to OTC has surpassed 200 worldwide, spanning centers across Europe, North America, and Asia.
The ASRM's 2019 committee opinion reclassifying OTC as non-experimental was a turning point: it shifted the procedure from a research-consent activity to a standard fertility-preservation option offered alongside egg and embryo freezing.
Because biological activity is arrested rather than merely slowed, there is no known theoretical upper limit on safe storage duration imposed by the cryobiology itself — successful pregnancies have followed tissue stored for over a decade, and even tissue frozen more than 20 years prior has, in reported cases, yielded viable follicles upon thaw.
In practice, storage duration is governed by patient circumstances rather than biology: time to complete cancer treatment and achieve remission, time to reach reproductive age (for tissue banked in childhood), and patient choice about when — or whether — to pursue transplantation and pregnancy.
When the patient is ready — typically after completing treatment, achieving remission, and confirming premature ovarian insufficiency — the banked cortical strips are thawed and surgically grafted back into the body. Over the following weeks, host blood vessels re-invade the avascular graft, dormant primordial follicles reactivate, and both hormonal and reproductive function can be restored.
Orthotopic transplantation places the thawed cortical strips back onto or into the remaining native ovary, or onto the pelvic peritoneum near the ovarian fossa. This site preserves the natural anatomical relationship with the fallopian tube, allowing spontaneous conception in addition to IVF — the great majority of reported live births have come from orthotopic grafts.
Heterotopic transplantation places strips at an easily accessible, easily monitored site away from the pelvis — commonly the forearm or anterior abdominal wall. This simplifies follow-up biopsies and avoids repeat pelvic surgery, and can restore endocrine (hormonal) function effectively, but spontaneous pregnancy is not possible since the tissue is disconnected from the reproductive tract — eggs must be retrieved surgically and used with IVF.
The choice depends on pelvic anatomy after prior surgery/radiotherapy, patient preference, and whether the priority is natural conception or straightforward monitoring.
The single greatest threat to a fresh graft is not the freeze-thaw process itself but the days immediately after transplantation: the strip has no blood supply until host vessels grow in from the surrounding tissue bed, a process called neovascularization or revascularization.
Revascularization typically begins within 48–72 hours and functional blood flow is usually established within about 5 days, but this ischemic window starves the tissue of oxygen and nutrients. A substantial fraction of follicles — commonly cited estimates range from 60% to 95% — are lost in this early "burnout" phase, either from ischemic injury or because the drop in inhibitory signaling triggers many dormant follicles to activate simultaneously and be lost before vessels can support their growth.
Surgeons and researchers are actively testing strategies to shorten this window: pro-angiogenic growth factors, platelet-rich plasma, scaffold materials, and even mechanically pre-vascularizing the graft site days before transplantation.
The ischemic window between transplantation and revascularization — not the freezing process — accounts for the largest single loss of follicles in the entire OTC pathway, making it the primary target of ongoing research to improve graft longevity.
Once perfusion is restored, surviving primordial follicles begin to reactivate: granulosa cells proliferate, the oocyte grows, and a fraction of the follicle cohort progresses through primary, secondary, and eventually antral stages capable of ovulation. Menstrual cyclicity and rising estradiol typically return within 4–6 months of a successful orthotopic graft, and can be tracked via AMH and antral follicle counts on ultrasound as an early proxy for graft function.
A transplanted cortical graft is not permanent: because it contains a finite, non-renewable follicle pool that was never replenished, and because it typically lacks the endocrine feedback regulation of a fully intact ovary, follicles are consumed at an accelerated rate compared to natural ovarian aging. Most grafts remain functional for roughly 2–7 years, after which hormone levels and fertility potential decline again — although some patients have experienced a decade or more of function, and repeat transplantation of additional banked strips is possible if more tissue remains in storage.
Since the first live birth in 2004, more than 200 babies have been born worldwide following ovarian tissue cryopreservation and transplantation, with pregnancy rates in eligible patients comparable to other assisted-reproduction fertility-preservation strategies — cementing OTC's place as a mainstream option rather than a last resort.